home home Korean

facebook

  • TPX-111 [SCS-allogeneic keratinocytes] IND review approved, Phase II
  • TPX-103 [SCS-autologous keratinocytes] Phase II clinical study completed
  • TPX-102 [SCS-allogeneic keratinocytes] IND review approved, Phase II
  • TPX-103 [SCS-autologous keratinocytes] IND review approved
  • kaloderm® PMS (for burn) approved
  • Technology transfer from Yonsei University
  • kaloderm® approval for smaller sizes
  • Holoderm® PMS approved
  • Kaloderm® receives marketing approval for diabetic foot ulcer
  • Neoderm® pre-validation completed
  • Kaloderm® Phase III clinical study completed for diabetic foot ulcer
  • Kaloderm® Phase III clinical study begins for diabetic foot ulcer
  • Kaloderm® IND review approved for diabetic foot ulcer
  • Kaloderm® approved for reimbursement by National Health Insurance
  • Workers' Compensation reimbursements approved for both Holoderm® and Kaloderm®
  • Recognized as one of 10 best new technologies by government
  • Cultured keratinocyte registered as a cosmetic ingredient by CTFA
  • Capital increased to KRW 786 million through common share issue
  • HT (Health Technology) recognition